Naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof

1 . A compound selected from a naphthyridinone derivative compound represented by the following Formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof:

wherein

R 1 is hydrogen, or a C 1 -C 6 alkyl group;

R 2 is —Z-A;

Z is present or absent, wherein when Z is present, Z is —NH—, or —(NC n H 2n+1 )—;

n is an integer from 1 to 6;

A is selected from the group consisting of:

X is halogen;

m is an integer from 0 to 3;

R 3 and R 4 are each independently hydrogen, or branched- or straight-chain C 1 -C 6 alkyl;

R 5 is hydrogen, S(O) 2 NH 2 , or S(O) 2 NH-Boc;

Y is NR 6 R 7 or P(O)R 8 R 9 ;

R 6 is hydrogen, branched- or straight-chain C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

R 7 is hydrogen, Boc, branched- or straight-chain C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 5 -C 6 aryl, C 5 -C 6 heteroaryl, S(O) 2 NH 2 , S(O) 2 NH-Boc, S(O) 2 (branched- or straight-chain C 1 -C 6 alkyl), S(O) 2 (C 3 -C 6 cycloalkyl), S(O) 2 (C 5 -C 6 aryl), or S(O) 2 (C 5 -C 6 heteroaryl), wherein said cycloalkyl, aryl, or heteroaryl is optionally substituted by branched- or straight-chain C 1 -C 6 alkyl; and

R 8 and R 9 are each independently hydroxy or C 1 -C 6 alkyloxy.

2 . The compound according to claim 1 , wherein R 1 is hydrogen or a C 1 -C 5 alkyl group.

3 . The compound according to claim 1 , wherein R 1 is hydrogen or a C 1 -C 3 alkyl group.

4 . The compound according to claim 1 , wherein the pharmaceutically acceptable salt is a salt of an inorganic or organic acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid.

5 . A pharmaceutical composition comprising the compound according to claim 1 as an active ingredient.

6 . An ENPP 1 inhibitor comprising the compound according to claim 1 as an active ingredient.

7 . A STING pathway activator comprising the compound according to claim 1 as an active ingredient.